A Study of Baricitinib in Participants With Rheumatoid Arthritis
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This post-marketing study is designed to compare the safety of baricitinib versus tumor
necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when
given to participants with rheumatoid arthritis (RA).